Macupatide (acetaat)

Macupatide acetate is a gastric inhibitory peptide (GIP) receptor agonist used in anti-diabetic research[1].

LY3532226 (acetate)

12352209

Insulin Receptor

Protein Tyrosine Kinase/RTK

Metabolic Disease

99.71

DMSO : 50 mg/mL (ultrasonic)

O=C(NC(C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@](C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)C(N[C@@H](CC3=CNC=N3)C(N[C@@H](CCC(N)=O)C(NC(C(N[C@@H](CC(O)=O)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC5=CC=NC=C5)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(NCC(N6[C@@H](CCC6)C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@@H](C)C(N7[C@@H](CCC7)C(N8[C@@H](CCC8)C(N9[C@@H](CCC9)C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)(C)C)=O)=O)=O)=O)=O)=O)=O)(CC(C)C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)(C)C)[C@H](CC%10=CC=C(C=C%10)O)N.CC(O)=O.[x]

C232H357N49O72.xC2H4O2

4984.60 (free base)

[1]Mari A, et al. Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial. Diabetes Care. 2025 Jul 22:dc250763.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10959A/Macupatide-acetate-SDS-MedChemExpress.pdf

Peptides

No Development Reported